About the Company
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.
Employees
241
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IOVA News
Iovance Biotherapeutics Inc IOVA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) is possibly approaching a major achievement in its business, so we ...
First Week of May 31st Options Trading For Iovance Biotherapeutics (IOVA)
Investors in Iovance Biotherapeutics Inc (Symbol: IOVA) saw new options begin trading this week, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Analyzing the Price-to-Earnings Ratio of Iovance Biotherapeutics Inc (IOVA)
Smart investors will not be hesitating on this one! The stock price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) has dropped by -3.64 compared to previous close of 12.36. Despite this, the company ...
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
Iovance Biotherapeutics, Inc. IOVA incurred a loss of 45 cents per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of 44 cents.In the year-ago quarter, the company ...
Iovance Biotherapeutics Enters Oversold Territory (IOVA)
In trading on Monday, shares of Iovance Biotherapeutics Inc (Symbol: IOVA) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $11.66 per share.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, ...
Iovance Biotherapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...